{"entity":{"id":"paper-gog-240-bevacizumab-cervical-nejm-2014","kind":"paper","name":"GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer","aka":[],"tldr":"Adding the anti-angiogenic antibody bevacizumab to chemotherapy lengthened survival by almost four months in recurrent or metastatic cervical cancer, the first targeted drug to improve survival in a gynaecological cancer.","summary":"Phase 3 factorial trial of 452 patients with recurrent, persistent or metastatic cervical cancer randomised to cisplatin-paclitaxel or topotecan-paclitaxel, with or without bevacizumab.\n\nMedian overall survival was 17.0 versus 13.3 months with bevacizumab (hazard ratio 0.71) and response 48 versus 36 percent; topotecan-paclitaxel was not superior to cisplatin-paclitaxel. Fistula occurred in about 6 percent of bevacizumab patients, mostly after prior radiotherapy.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2014","url":"https://doi.org/10.1056/NEJMoa1309748"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24552320/"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2014,"doi":"10.1056/NEJMoa1309748","pmid":"24552320","authors":"Tewari KS, Sill MW, Long HJ, et al.","paperType":"rct","findings":["Median overall survival 17.0 vs 13.3 months; hazard ratio 0.71.","Objective response 48 percent vs 36 percent."],"whatItMeans":"Platinum-paclitaxel with bevacizumab became the first-line standard for advanced cervical cancer and remains the backbone to which pembrolizumab is added.","caveats":["Gastrointestinal and genitourinary fistulas in irradiated patients.","Hypertension and thromboembolism increased."],"changedPractice":true,"participants":452},"route":"/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/","neighbours":{"cancer":[{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}